| Literature DB >> 32871388 |
Binyin Li1, Miao Zhang2, Joost Riphagen3, Kathryn Morrison Yochim3, Biao Li2, Jun Liu4, David H Salat5.
Abstract
Structural neuroimaging has been applied to the identification of individuals with Alzheimer's disease (AD) and mild cognitive impairment (MCI). However, these methods are greatly impacted by age limiting their utility for detection of preclinical pathology. We built linear models for age based on multiple combined structural features using a large independent lifespan sample of 272 healthy adults across a wide age range from the Human Connectome Project Aging study. These models were then used to create a new support vector machine (SVM) training model in 136 AD and 268 control participants based on residues of fit from the expected age-effects relationship. Subsequent validation assessed the accuracy of the SVM model in new datasets. Finally, we applied the classifier to 276 individuals with MCI to evaluate prediction for early impairment and longitudinal cognitive change. The optimal 10-fold cross-validation accuracy was 93.07%, compared to 91.83% without age detrending. In the validation dataset, the classifier for AD obtained an accuracy of 84.85% (56/66), sensitivity of 85.36% (35/41) and specificity of 84% (21/25). Classification accuracy was improved when using the lifespan sample as opposed to the classification sample. Importantly, we observed cross-sectional greater AD specific biomarkers, as well as faster cognitive decline in MCI who were classified as more 'AD-like' (MCI-AD), and these effects were pronounced in individuals who were late MCI. The top five contributive features were volumes of left hippocampus, right hippocampus, left amygdala, the thickness of left and right middle temporal & parahippocampus gyrus. Linear detrending for age in SVM for combined structural features resulted in good performance for recognition of AD and AD-specific biomarkers, as well as prediction of MCI progression. Such procedures may be used in future work to enhance prediction in samples with atypical age distributions.Entities:
Keywords: Age detrending; Alzheimer’s disease; Multi-feature MRI; Neuroimage
Mesh:
Substances:
Year: 2020 PMID: 32871388 PMCID: PMC7476071 DOI: 10.1016/j.nicl.2020.102387
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.891
Participants demographics from the three datasets.
| Dataset 1 | Dataset 2 (ADNI) | Dataset 2-plus (ADNI) | Dataset 3 | ||||
|---|---|---|---|---|---|---|---|
| HCP | AD | CN | AD | CN | AD | CN | |
| N | 272 | 136 | 268 | 119 | 181 | 41 | 25 |
| Sex (F/M) | 146/126 | 57/79 | 148/120 | 55/64 | 87/94 | 19/22 | 12/13 |
| Age (year) | 62.7 ± 16.8 | 74.2 ± 8.2 | 72.9 ± 6.0 | 73.8 ± 8.2 | 71.9 ± 5.9 | 68.7 ± 9.0 | 68.5 ± 6.1 |
| Education (year) | 15.3 ± 4.5 | 15.7 ± 2.5 | 16. 6 ± 2.5 | 15.6 ± 2.5 | 16. 8 ± 2.4 | 12.3 ± 3.3 | 13.2 ± 3.1 |
| MoCA | 26.2 ± 2.6 | 17.2 ± 4.5 | 25.8 ± 2.4 | 17.2 ± 4.5 | 25.9 ± 2.5 | 16.2 ± 6.8 | 27.2 ± 1.8 |
| MMSE | – | 23.0 ± 2.1 | 29.1 ± 1.1 | 23.1 ± 2.1 | 29.1 ± 1.2 | 20.7 ± 6.2 | 27.9 ± 2.0 |
| ACE-R | – | – | – | – | – | 60.5 ± 21.9 | 84.6 ± 18.6 |
HCP, human connectome project; AD, Alzheimer’s disease; CN, cognitively normal; F, female; M, male; MMSE, mini-mental state examination; MoCA, Montreal cognitive assessment; ACER, Addenbrooke's cognitive examination-revised.
Classification performance of models based on age detrending from different samples.
| Model | Detrending model from D1 | Detrending model from sub-D1 | Detrending model from D2 control | Detrending model from D2-plus control |
|---|---|---|---|---|
| N | 272 | 134 | 268 | 181 |
| Age span | 36 - >100 | 55–85 | 56–90 | 56–89 |
| Accuracy within SVM | 392/404 (97.03%) | 395/404 (97.77%) | 384/404 (95.05%) | 285/300 (95.00%) |
| Sensitivity within SVM | 128/136 (94.12%) | 129/136 (94.85%) | 119/136 (87.50%) | 107/119 (89.92%) |
| Specificity within SVM | 264/268 (98.51%) | 266/268 (99.25%) | 265/268 (98.88%) | 178/181 (98.34%) |
| Accuracy in D3 | 56/66 (84.84%) | 53/66 (80.30%) | 51/66 (77.27%) | 54/66 (81.82%) |
| Sensitivity in D3 | 35/41 (85.36%) | 33/41 (80.49%) | 29/41 (70.73%) | 32/41 (78.05%) |
| Specificity in D3 | 21/25 (84.00%) | 20/25 (80.00%) | 22/25 (88.00%) | 22/25 (88.00%) |
SVM, support vector machine.
Fig. 1Different residuals from regression in AD and controls. Left: In each heatmap, columns represented participants, and rows represented regional difference between the actual measure and predicted one from age regression line (each row rescaled by max–min normalization across two groups, with the maximum = 1 and minimum = 0). The darker color showed relatively more negative residual, while lighter color suggested more positive residual when rows were compared between AD and controls from D2. Right: Averaged difference between value of each row in two groups from the left heatmap (normal controls - AD). The regions that the rows represented were marked on the right. AD, Alzheimer’s disease; GWR, ratio of gray to white matter signal intensity.
Fig. 2Mapping of most contributive features for classification. Maps of subcortical volumes and cortical thickness with F-score>0.3, in the SVM classifier from the controls and AD groups in D2.
Fig. 3Longitudinal changes in classified MCI. Boxplot of cognitive performance at each visit for MCI. MMSE, mini-mental state examination; MoCA, Montreal cognitive assessment; ADAS: Alzheimer’s Disease Assessment Scale Cognitive Subscale; RAVLT, Rey’s auditory verbal learning test; TMT-B, trail making test-B; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; CN, control; bl, baseline; m, month. *** p < 0.001, ** p < 0.01.
The classification of MCI and longitudinally cognitive changes.
| EMCI | LMCI | |||||
|---|---|---|---|---|---|---|
| AD | CN | P-value | AD | CN | P-value | |
| N | 29 | 151 | – | 41 | 55 | – |
| Age | 72.9 ± 6.0 | 70.2 ± 6.9 | 0.031 | 73.3 ± 6.4 | 69.0 ± 7.3 | 0.002 |
| Sex (F/M) | 12/17 | 66/85 | 0.978 | 23/18 | 26/29 | 0.516 |
| Amyloid PET | 1.2 ± 0.2 | 1.2 ± 0.1 | 0.861 | 1.2 ± 0.2 | 1.4 ± 0.2 | <0.001 |
| FDG PET | 1.2 ± 0.1 | 1.3 ± 0.1 | 0.008 | 1.1 ± 0.1 | 1.3 ± 0.1 | <0.001 |
| p-tau (ng/l) | 24.4 ± 13.7 | 25.6 ± 14.9 | 0.518 | 39.8 ± 15.0 | 27.7 ± 14.4 | 0.002 |
| Education | 16.5 ± 3.0 | 16.5 ± 2.6 | 0.407 | 16.9 ± 2.6 | 16.2 ± 2.6 | 0.167 |
| EMCI | LMCI | |||||
| Interaction* (p-value) | Effect estimate (Beta) | 95% CI of Beta | Interaction* (p-value) | Effect estimate (Beta) | 95% CI of Beta | |
| ADAS-13 | m36 (0.020) | 3.60 | 1.25–5.95 | m24 (<0.001) | 5.07 | 2.10–8.03 |
| MMSE | m06 (0.003) | −1.32 | −2.20 to −0.45 | m24 (0.002) | −2.00 | −3.30 to −0.71 |
| MOCA | – | – | – | m24 (0.001) | −2.25 | −3.63 to −0.88 |
| RAVLT-learning | m36 (0.047) | −1.14 | −2.26 to −0.01 | – | – | – |
| RAVLT-forgetting | m12 (0.002) | −1.92 | −3.16 to −0.67 | – | – | – |
| TMT-B | – | – | – | m12 (0.024) | 27.3 | 3.62–51.1 |
* Interaction between follow-up and classification, with baseline as reference, only shown with p < 0.05.
Data are given in mean values (standard deviation, SD), if not otherwise specified. m, month of follow-up; M, male; F, female. AD, Alzheimer’ disease; CN, cognitively normal; EMCI, early MCI; LMCI, late MCI; N, number of subjects; p-tau, phosphorylated tau in cerebrospinal fluid; MMSE, mini-mental state examination; MoCA, Montreal cognitive assessment; ADAS: Alzheimer’s Disease Assessment Scale Cognitive Subscale; RAVLT, Rey’s auditory verbal learning test; TMT-B, trail making test-B.
Global neocortical uptake relative a composite reference region in florbetapir PET.
Global neocortical uptake relative a composite reference region in fluorodeoxyglucose PET.
Adjusted for age, sex and years of education.
Cognitive changes in age and education matched group for EMCI-AD and LMCI-AD.
| EMCI | LMCI | |||||
|---|---|---|---|---|---|---|
| AD | CN | P-value | AD | CN | P-value | |
| N | 29 | 29 | – | 41 | 41 | – |
| Age | 72.9 ± 6.0 | 73.6 ± 7.2 | 0.702 | 73.3 ± 6.4 | 71.6 ± 6.0 | 0.234 |
| Sex (Female/Male) | 12/17 | 12/17 | 0.978 | 23/18 | 18/23 | 0.377 |
| Education | 16.5 ± 3.0 | 15.9 ± 2.6 | 0.406 | 16.9 ± 2.1 | 16.7 ± 2.4 | 0.735 |
| MMSE-Baseline | 28.3 ± 1.6 | 28.3 ± 1.6 | 0.933 | 27.0 ± 1.7 | 28.0 ± 1.7 | 0.007 |
| Follow up* | Ns | – | m24 | 0.003 | ||
| MOCA-Baseline | 21.9 ± 2.4 | 24.5 ± 2.7 | <0.001 | 20.6 ± 2.5 | 23.6 ± 3.1 | <0.001 |
| Follow up* | m48 | 0.054 | m24 | 0.008 | ||
| ADAS-Baseline | 17.0 ± 5.9 | 12.0 ± 5.0 | <0.001 | 22.3 ± 5.8 | 16.4 ± 6.3 | <0.001 |
| Follow up* | m48 | 0.007* | m24 | <0.001 | ||
*Significant interaction between follow-up and classification, with baseline as reference; m, month of follow-up. AD, Alzheimer’s disease; CN, cognitively normal; EMCI, early MCI; LMCI, late MCI; N, number of subjects.